With top notch personnel, the factory, the cash injection, the...

With top notch personnel, the factory, the cash injection, the promising early results, the interests from oncology practitioners, the FDA support and the recent job advertisement, you could be forgiven for thinking that IMU is looking more and more enticing as a 'turn key' solution for a BP looking to bolster their corporate assets and future by acquiring a whole owned subsidiary in oncology research and development, which can fit into their sales, marketing and distrbution infrastructure.
A mini Genetech or 'IMU 2.0' indeed!
dyor.